The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Open accessAbstract
Purpose: The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy. Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL). We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL. Patients and Methods: Patients were treated with oral lenalidomide 25 mg once daily on days 1 to 21, every 28 days, for 52 weeks, until disease progression or intolerance. The primary end point was response; secondary end points included duration of response, progression-free survival (PFS), and safety. Results: Forty-nine patients with a median age of 65 years received lenalidomide in this study. The most common histology was diffuse large B-cell lymphoma (53%), and patients had received a median of four prior treatment regimens for NHL. An objective response rate of 35% was observed in 49 treated patients, including a 12% rate of complete response/unconfirmed complete response. Responses were observed in each aggressive histologic subtype tested (diffuse large B-cell, follicular center grade 3, mantle cell, and transformed lymphomas). Of patients with stable disease or partial response at first assessment, 25% improved with continued treatment. Estimated median duration of response was 6.2 months, and median PFS was 4.0 months. The most common grade 4 adverse events were neutropenia (8.2%) and thrombocytopenia (8.2%); the most common grade 3 adverse events were neutropenia (24.5%), leukopenia (14.3%), and thrombocytopenia (12.2%). Conclusion: Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationFeugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.131 · Cited by 1,486
Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1003 · Cited by 1,355
Self-citationCoiffier, B., Haïoun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D. D. F., Johnson, P., Lister, A., Feuring‐Buske, M., Radford, J. A., et al. (1998) · PubMed · doi:10.1182/blood.v92.6.1927 · Cited by 893
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K., & Dalgleish, A. G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1323 · Cited by 809
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationPhilip, T., Armitage, J. O., Spitzer, G., Chauvin, F., Jagannath, S., Cahn, J.-Y., Colombat, P., Goldstone, A. H., Gorin, N. C., Flesh, M., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706113162401 · Cited by 771
Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E., Hagemeister, F., Fayad, L., Dang, N. H., Samaniego, F., Wang, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.108 · Cited by 526
Cited by
The tumour microenvironment in B cell lymphomas
Scott, D. W., & Gascoyne, R. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3774 · Cited by 552
Salles, G., Duell, J., González Barca, E., Tournilhac, O., Jurczak, W., Liberati, A. M., Nagy, Z., Obr, A., Gaidano, G., André, M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30225-4 · Cited by 533
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Friedberg, J. W. (2011) · Hematology · doi:10.1182/asheducation-2011.1.498 · Cited by 497
Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Liu, Y., & Barta, S. K. (2019) · American Journal of Hematology · doi:10.1002/ajh.25460 · Cited by 488
Mechanism of action of lenalidomide in hematological malignancies
Kotla, V., Goel, S., Nischal, S., Heuck, C., Vivek, K., Das, B., & Verma, A. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 467
Martelli, M., Ferreri, A. J. M., Agostinelli, C., Di Rocco, A., Pfreundschuh, M., & Pileri, S. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.12.009 · Cited by 456
Witzig, T. E., Vose, J. M., Zinzani, P. L., Reeder, C. B., Buckstein, R., Polikoff, J. A., Bouabdallah, R., Haioun, C., Tilly, H., Guo, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq626 · Cited by 392
Self-citationNowakowski, G. S., LaPlant, B., Macon, W. R., Reeder, C. B., Foran, J. M., Nelson, G. D., Thompson, C. A., Rivera, C. E., Inwards, D. J., Micallef, I. N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5714 · Cited by 359
Self-citationGoy, A., Sinha, R., Williams, M. E., Kalayoglu Besisik, S., Drach, J., Ramchandren, R., Zhang, L., Cicero, S., Fu, T., & Witzig, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2835 · Cited by 349
Hernandez‐Ilizaliturri, F. J., Deeb, G., Zinzani, P. L., Pileri, S. A., Malik, F., Macon, W. R., Goy, A., Witzig, T. E., & Czuczman, M. S. (2011) · Cancer · doi:10.1002/cncr.26135 · Cited by 304
Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma
Gribben, J. G., Fowler, N., & Morschhauser, F. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5363 · Cited by 296
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Witzig, T. E., Reeder, C. B., LaPlant, B. R., Gupta, M., Johnston, P. B., Micallef, I. N., Porrata, L. F., Ansell, S. M., Colgan, J. P., Jacobsen, E. D., et al. (2011) · Leukemia · doi:10.1038/leu.2010.226 · Cited by 297
Self-citationWang, M., Fayad, L., Wagner-Bartak, N., Zhang, L., Hagemeister, F., Neelapu, S. S., Samaniego, F., McLaughlin, P., Fanale, M., Younes, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70200-0 · Cited by 297
Self-citationNowakowski, G. S., Chiappella, A., Gascoyne, R. D., Scott, D. W., Zhang, Q., Jurczak, W., Özcan, M., Hong, X., Zhu, J., Jin, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01366 · Cited by 275
Fowler, N. H., Davis, R. E., Rawal, S., Nastoupil, L., Hagemeister, F. B., McLaughlin, P., Kwak, L. W., Romaguera, J. E., Fanale, M. A., Fayad, L. E., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70455-3 · Cited by 264
Witzig, T. E., Wiernik, P. H., Moore, T., Reeder, C., Cole, C., Justice, G., Kaplan, H., Voralia, M., Pietronigro, D., Takeshita, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1169 · Cited by 260
Self-citationHagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., et al. (2015) · Blood · doi:10.1182/blood-2015-02-628669 · Cited by 203
Ishida, T., Fujiwara, H., Nosaka, K., Taira, N., Abe, Y., Imaizumi, Y., Moriuchi, Y., Jo, T., Ishizawa, K., Tobinai, K., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.7732 · Cited by 152
Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells
Shenoy, N., Bhagat, T., Nieves, E., Stenson, M., Lawson, J., Choudhary, G. S., Habermann, T., Nowakowski, G., Singh, R., Wu, X., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.65 · Cited by 111
Self-citationThe clinical significance of cereblon expression in multiple myeloma
Schuster, S. R., Kortuem, K. M., Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Ahmann, G., Kumar, S., Rajkumar, S. V., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2013.08.015 · Cited by 113
Querfeld, C., Rosen, S. T., Guitart, J., Duvic, M., Kim, Y. H., Dusza, S. W., & Kuzel, T. M. (2014) · Blood · doi:10.1182/blood-2013-09-525915 · Cited by 93
“In particular, lenalidomide has shown promise in several studies in patients with NHL (not including CTCL), including in patients with relapsed/refractory disease.(26-29) Despite the rationale for using lenalidomide in patients with CTCL, data on this treatment approach are lacking.”
BackgroundThe application and biology of immunomodulatory drugs (IMiDs) in cancer
Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76
Nardone, B., Wu, S., Garden, B. C., West, D. P., Reich, L. M., & Lacouture, M. E. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.03.006 · Cited by 44
Novel disease targets and management approaches for diffuse large B-cell lymphoma
Wilson, W. H., Hernandez-Ilizaliturri, F. J., Dunleavy, K., Little, R. F., & O'Connor, O. A. (2010) · Leukemia & Lymphoma · doi:10.3109/10428194.2010.500045 · Cited by 34
Metadata
- Authors
- Wiernik, P. H., Lossos, I. S., Tuscano, J. M., Justice, G., Vose, J. M., Cole, C. E., Lam, W., McBride, K., Wride, K., Pietronigro, D., Takeshita, K., Ervin-Haynes, A., Zeldis, J. B., & Habermann, T. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-10-20
- Volume
- 26
- Issue
- 30
- Pages
- 4952-4957
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2153558008
- Cited by
- 371
- References
- 21
- FWCI
- 18.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.